Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Henry G. Kaplan"'
Autor:
Jeanna Wallenta Law, Debanjali Mitra, Henry G. Kaplan, Tamuno Alfred, Adam M. Brufsky, Birol Emir, Haley McCracken, Xianchen Liu, Ronda G. Broome, Chenan Zhang, Caroline DiCristo, Connie Chen
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 1047-1061 (2022)
This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC)
Externí odkaz:
https://doaj.org/article/f8c89b12620c474d8fca86acf4db753d
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Lead time, the interval between screen detection and when a disease would have become clinically evident, has been cited to explain longer survival times in mammography detected breast cancer cases (BC). Methods An institutional r
Externí odkaz:
https://doaj.org/article/e564dbeca93a41c1b152c3653cc8258a
Autor:
Della Varghese, Giovanna I. Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C. Faherty, David Harland, Henry G. Kaplan
Publikováno v:
Cancer Research. 83:P1-11
Background. Standard-of-care treatment for HER2-positive metastatic breast cancer (HER2+ mBC) patients has traditionally included targeted therapies such as trastuzumab and/or pertuzumab in first line (1L) and ado-trastuzumab emtansine (T-DM1) in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38d6a9cefa9b1a1348b00ad7ea93d476
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-19
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-19
Autor:
Jeanna Wallenta Law, Alicyn Campbell, Colin Weller, Colden Johanson, Ronda Broome, Elisabeth Piault, Monika Izano, Andrew Schrag, Mary Tran, Thomas D. Brown, Henry G. Kaplan
Publikováno v:
Breast Cancer Research and Treatment. 196:603-611
Purpose Using real-world data, interstitial lung disease (ILD) prevalence before and after HER2-directed therapy was estimated. Potential ILD risk factors in patients receiving HER2-directed therapy for metastatic breast cancer (mBC) were evaluated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1551e13d8609077a1678f529c429f51
https://doi.org/10.1007/s10549-022-06738-6
https://doi.org/10.1007/s10549-022-06738-6
Publikováno v:
The Oncologist. 27:e661-e670
Background This review summarizes the case studies of PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia. Recommended treatment includes JAK2 inhibitors and hematologic stem cell transplantation (HSCT), although the small number of patients has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c277e5a538de5bab02235a3149136899
https://doi.org/10.1093/oncolo/oyac072
https://doi.org/10.1093/oncolo/oyac072
Publikováno v:
Cancer Research. 82:P3-08
Background: Simultaneous ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC) is very common. However, it is not clear how often these histologies are clonally related or the mechanism by which DCIS evolves into IBC. In this study we eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cce19c76499ed23aa689b9c9a8c5fea
https://doi.org/10.1158/1538-7445.sabcs21-p3-08-05
https://doi.org/10.1158/1538-7445.sabcs21-p3-08-05
Publikováno v:
International Journal of Cancer Care and Delivery. 2
Recent advances in bioengineering and manufacturing have catapulted Antibody–drug conjugates (ADCs) to broader clinical applications. ADCs take advantage of the exquisite specificity of monoclonal antibodies (mAb) to deliver a highly potent cytotox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45a371a1c8f890ca98408a073277f3a4
https://doi.org/10.53876/001c.33661
https://doi.org/10.53876/001c.33661
Publikováno v:
Breast cancer research and treatment. 195(2)
Purpose The optimal duration of first-line trastuzumab (T) treatment for de novo stage IV HER2-positive metastatic breast cancer (MBC) patients after complete response (CR) is not known. Methods A retrospective cohort study of de novo stage IV HER2-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bf53ff2360c18aa4d751c58284a2a23
https://pubmed.ncbi.nlm.nih.gov/35869377
https://pubmed.ncbi.nlm.nih.gov/35869377
Autor:
Fengting Yan, Kristine J. Rinn, Jonathon A. Kullnat, Aimee Y. Wu, Maura D. Ennett, Elizabeth L. Scott, Henry G. Kaplan
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 20(7)
Metastatic breast cancer demonstrates HER2/neu amplification approximately 15% of the time. However, HER2 mutations, which often stimulate tumor growth, occur in only 3% to 5% of patients, and are seen more frequently in metastatic versus primary tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d336b43b9e94ea8c689839f4c01b9b84
https://pubmed.ncbi.nlm.nih.gov/35405660
https://pubmed.ncbi.nlm.nih.gov/35405660
Autor:
Lisa M. Frenkel, Daisy Ko, Jennifer Hadlock, Venkata R Duvvuri, Samantha Hardy, John D. Aitchison, William Chour, Jackson Wallner, Alyssa Oldroyd, Henry G. Kaplan, Andrew Raappana, James R. Heath, Yonghou Jiang, Ana Gervassi, Winnie Yeung, Jason D Goldman, Sheila Styrchak, Whitney E. Harrington, Micaela Haglund, Kim Murray, Fergal J. Duffy, John Houck, Julie A. Wallick, D. Noah Sather, Ingrid A. Beck
BACKGROUNDCoronavirus disease 2019 (COVID-19) is associated with endothelial activation and coagulopathy, which may be related to pre-existing or infection-induced pro-thrombotic autoantibodies such as those targeting angiotensin II type I receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1adec9dd28cd8950c637cf71cfd08e28
https://doi.org/10.1101/2021.06.30.21259796
https://doi.org/10.1101/2021.06.30.21259796
